Home About Us People Prof. Dr. Denis Poddubnyy
Spondyloarthritides
Prof. Dr. Denis Poddubnyy

Spondyloarthritides

Prof. Dr. Denis Poddubnyy

Leiter der Rheumatologie in der Medizinischen Klinik für
Gastroenterologie, Infektiologie und Rheumatologie an der
Charité - Universitätsmedizin Berlin
Campus Benjamin Franklin
Hindenburgdamm 30
12203 Berlin
Phone: +49 (0)30 450 514 582 Denis.Poddubnyy@charite.de

CV and Key Publications

Scientific Career
  • Since 2016 Head of the liaison group “Spondyloarthritiden”, Program Area “”Epidemiology”, DRFZ
  • Since 2016 Professor (W2), Head of the Rheumatology Group, Department of Gastroenterology, Infectiology and Rheumatology, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin
  • 2014 – 2016 Coordinator of the Clinical Research Unit (CRU), Campus Benjamin Franklin, Charité- Universitätsmedizin Berlin and Berlin Institute of Health (BIH),
  • 01.2014 Postdoctoral lecture qualification (Habilitation) “Prediction and prevention of dis-ease progression in early axial spondyloarthritis”, Charité-Universitätsmedizin Berlin
  • 2008 – 2016 Research associate, Department of Gastroenterology, Infectiology and Rheumatology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin
  • 2008 PhD Thesis “The role of endothelial dysfunction in the cardiovascular pathology de-velopment in patients with ankylosing spondylitis”, Saratov State Medical University
  • 2003 – 2008 Research associate, Saratov State Medical, Saratov, Russian Federation
Education
  • 2014 – 2016 Master of Science in Epidemiology, Berlin School of Public Health, Charité- Universitätsmedizin Berlin
  • 2014 Board certified in internal medicine and rheumatology, Chamber of Physicians, Berlin
  • 2008 – 2013 Training in Internal Medicine and Rheumatology – Department of Gastroenterology, Infectiology and Rheumatology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin
  • 2003 – 2008 Training in internalmedicine and rheumatology, Saratov State Medical University / Saratov Region Hospital, Saratov, Russian Federation and Charité-Universitäts-medizin Berlin, Berlin
  • 2003 Qualification as physician
  • 1997 – 2003 Medical School, Saratov State Medical University, Saratov, Russian Federation
Boards
  • Since 2018 Member of the Executive Committee of the ASAS (Assessment of Spondyloarthritis International Society)
  • Since 2018 Editorial board member at “Therapeutic Advances in Musculoskeletal Disease”
  • 2012 – 2015 Member of the Working Group von EMEUNET (Emerging EULAR Network)
  • 2013 – 2017 Associated editor at “BMC Musculoskeletal Disorders”
Memberships
  • Since 2017 Member of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
  • Since 2017 Member of the American College of Rheumatology (ACR)
  • Since 2014 Member of the German Rheumatology Society (DGRh)
  • Since 2009 Member of the ASAS (Assessment of Spondyloarthritis International Society)
Awards
  • 2011, 2013, 2015, 2017 Poster awards of the German Rheumatology Society (DGRh)
  • 2012 Research award of the „Deutsche Vereinigung Morbus Bechterew e.V.”
Key Publications
  1. Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73-84.
  2. Poddubnyy D, Protopopov M, Haibel H, Braun J, Rudwaleit M, Sieper J. High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloar- thritis Inception Cohort. Ann Rheum Dis. 2016;75(12):2114-2118.
  3. Poddubnyy D, Listing J, Sieper J. Course of active inflammatory and fatty lesions in patients with early axial spondyloarthritis treated with infliximab plus naproxen as compared to naproxen alone: Results from the INFAST study. Arthritis Rheumatol. 2016 Aug;68(8):1899-903.
  4. Poddubnyy D, Haibel H, Braun J, Rudwaleit M, Sieper J. Clinical course over two years in patients with early non-radiographic axial spondyloarthritis and ankylosing spondylitis without anti-TNFα treatment. Arthritis Rheumatol. 2015 Sep;67(9):2369-75.
  5. Poddubnyy D, van Tubergen A, Landewé R, Sieper J, van der Heijde D. Development of an ASAS endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. Ann Rheum Dis 2015 Aug;74(8):1483-7.
  6. Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 2014;73:817-23.
  7. Poddubnyy D, Conrad K, Haibel H, Syrbe U, Haibel H, Appel H, Braun J, Rudwaleit M, Sieper J. Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. Ann Rheum Dis 2014;73:2137-43.
  8. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, Sieper J. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German SPondyloarthritis Inception Cohort (GESPIC). Ann Rheum Dis 2012;71(10):1616-22.
  9. Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, Sieper J, Rudwaleit M. Base- line radiographic damage, elevated acute phase reactants and cigarette smoking status predict radiographic progression in the spine in early axial spondyloarthritis. Arthritis Rheum 2012;64(5):1388- 98.
  10. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, Sieper J. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloar- thritis. Ann Rheum Dis 2011;70(8):1369-74.
Poddubnyy lab
Early diagnosis and effective therapy of chronic inflammatory spine disease